TY  - RPRT
TI  - Therapeutic benefits of maintaining CDK4/6 inhibitors and incorporating CDK2 inhibitors beyond progression in breast cancer
AU  - Armand, J.
AU  - Kim, S.
AU  - Kim, K.
AU  - Son, E.
AU  - Kim, M.
AU  - Yang, H. W.
PY  - 2024
DO  - 10.1101/2024.11.11.623139
UR  - https://www.biorxiv.org/content/10.1101/2024.11.11.623139v1
ID  - 10.1101/2024.11.11.623139
ER  -